Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deep vs Moderate NMB on Remifentanil Requirements in Gastrectomy
NCT04205097Completed
- Sponsor
- Ajou University School of Medicine
- Start
- Dec 2019
- Primary completion
- Dec 2020
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of Sugammadex in gastric cancer (GC) (2 arms), sponsored by Ajou University School of Medicine. Primary endpoint: Total dose of remifentanil. Started Dec 2019; status: completed.
02
Drugs
Sugammadex
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04205097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04205097.